More than 20 years after gaining FDA approval for Flovent, GSK still controlled the market in the U.S. for the asthma inhaler through a partnership with an “authorized generic” dealer, a setup that ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

GSK struck a $950 million deal to buy Canada’s 35Pharma, a biopharmaceutical company developing cardiopulmonary treatments, as the U.K. drugmaker seeks to bolster its exposure to diseases linked to ...

Acquisition boosts drugmaker's pipeline of respiratory medicines 35Pharma's drug has shown promise in mouse studies for obesity-related heart condition GSK shares have risen nearly 21% so far this ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — Building up its base of medicines for lung diseases, GSK said ...

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Bora Pharmaceuticals Co., Ltd. (“Bora”; TWSE: 6472; OTCQX: BORAY), a global leader in pharmaceutical manufacturing, and GSK (LSE/NYSE: GSK) have signed a ...

GSK (GSK) shares clocked seven straight sessions of gains, as the stock rose 1.7% at $60.19 on Friday. The multinational healthcare giant gained 16.8% in the preceding six sessions. The stock has ...

GSK Plc’s new chief executive officer plans to speed up research and development and look for acquisitions as the British drugmaker tries to convince investors it can offset a looming patent cliff.

(RTTNews) - British drug major GSK plc (GSK, GSK.L) reported Wednesday higher profit and revenues in its fourth quarter, and issued fiscal 2026 outlook, expecting increase in core profit and turnover.

GSK plc GSK announced that it has entered into a definitive agreement to acquire California-based biotech RAPT Therapeutics RAPT for an estimated aggregate equity value of $2.2 billion. The impending ...

GSK gains global rights to ozureprubart, excluding parts of Asia RAPT's ozureprubart targets antibody causing allergic reactions Deal is GSK's first major acquisition under new CEO Luke Miels The deal ...

GSK Plc agreed to buy Rapt Therapeutics, a US-based biotech developing treatments for patients with inflammatory and immunologic diseases, in a deal valued at $2.2 billion. The UK drug company will ...